|1.||Fisher, Abraham: 3 articles (01/2008 - 08/2002)|
|2.||Billings, Lauren M: 1 article (03/2006)|
|3.||Martinez-Coria, Hilda: 1 article (03/2006)|
|4.||Green, Kim N: 1 article (03/2006)|
|5.||Oddo, Salvatore: 1 article (03/2006)|
|6.||Caccamo, Antonella: 1 article (03/2006)|
|7.||LaFerla, Frank M: 1 article (03/2006)|
|8.||Brandeis, Rachel: 1 article (08/2002)|
|9.||Kliger-Spatz, Michal: 1 article (08/2002)|
|10.||Bar-Ner, Rachel Haring Nira: 1 article (08/2002)|
|1.||Alzheimer Disease (Alzheimer's Disease)
03/02/2006 - "We investigated the therapeutic efficacy of the selective M1 muscarinic agonist AF267B in the 3xTg-AD model of Alzheimer disease. "
08/01/2002 - "AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease."
01/01/2008 - "The M1 muscarinic receptor (M1 mAChR) is a therapeutic target in Alzheimer's disease (AD) and the M1-selective muscarinic agonists AF102B, AF150(S) and AF267B are cognitive enhancers and potential disease modifiers. "
|2.||Sjogren's Syndrome (Sjogren Syndrome)
08/01/2002 - "The M1 muscarinic agonists AF102B (Cevimeline, EVOXACTM: prescribed in USA and Japan for Sjogren's Syndrome), AF150(S) and AF267B--1) are neurotrophic and synergistic with neurotrophins such as nerve growth factor and epidermal growth factor; 2) elevate the non-amyloidogenic amyloid precursor protein (alpha-APPs) in vitro and decrease beta-amyloid (A beta) levels in vitro and in vivo; and 3) inhibit A beta- and oxidative-stress-induced cell death and apoptosis in PC12 cells transfected with the M1 muscarinic receptor. "
|2.||Muscarinic M1 Receptor
|4.||Nerve Growth Factor (NGF)
|5.||Nootropic Agents (Nootropics)
|6.||Nerve Growth Factors (Neurotrophins)
|7.||Epidermal Growth Factor (EGF)
|8.||Amyloid (Amyloid Fibrils)
|1.||Investigational Therapies (Experimental Therapy)